An Crepel Belgian Reimbursement Update - October 2026 The Belgian reimbursement update effective 1 October 2026 brings several meaningful access developments across respiratory disease, bone and mineral metabolism, nephrology and neurology. The strongest... Sep 28, 2026 Farmanaut Market Access Insights
An Crepel Belgian Reimbursement Update - September 2026 September 2026 brings a substantial Belgian reimbursement update, with relevant patient access changes across oncology, pulmonary arterial hypertension, rare diseases, transplantation, dermatology, ne... Aug 28, 2026 Farmanaut Market Access Insights
An Crepel Belgian Reimbursement Update - August 2026 The Belgian reimbursement changes effective 1 August 2026 introduce several new treatment options, alongside targeted closures and practical improvements in prescribing and renewal. Below is a curated... Jul 30, 2026 Farmanaut Market Access Insights
An Crepel Belgian Reimbursement Update – July 2026 Targeted access gains, tighter legacy routes The July 2026 update shows three clear signals. First, access broadening continues in selected high-need and specialist-driven areas, particularly in infla... Jun 28, 2026 Farmanaut Market Access Insights
An Crepel Belgian Reimbursement Update – June 2026 Selected access changes across key treatment areas June 2026 brings a diverse Belgian reimbursement update, with relevant patient access changes across osteoporosis, rare diseases, vaccines, oncology,... May 28, 2026 Farmanaut Market Access Insights
An Crepel Belgian Reimbursement Update - May 2026 Immuno-oncology, hATTR and neurology stand out The Belgian reimbursement update effective 1 May 2026 is a broad one, but not every change carries the same market access signal. Several updates are adm... Apr 27, 2026 Farmanaut Market Access Insights
